Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function.
Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function.
复制标题
DOI：
10.1155/2009/616054
复制
发表时间：
2009
影响因子：
2
通讯作者：
Mortensen PB
中科院分区：
文献类型：
--
作者：
Jeppesen PB;Lund P;Gottschalck IB;Nielsen HB;Holst JJ;Mortensen J;Poulsen SS;Quistorff B;Mortensen PB
背景和目标。在一项短期研究中，胰升糖素样肽2(GLP-2)被证明可以改善短肠综合征(SBS)患者的肠道吸收。这项研究描述了两年来与GLP-2治疗相关的纵向变化。方法：研究方法。11例SBS患者给予GLP-2400微克，sc，tid，维持肠外支持恒定。72小时的营养平衡研究在基线、13周、26周、52周进行，间隔两年的时间为8周。此外，还测量了肾粘膜形态计量学、肾功能(内生肌酐清除法)、体成分和骨密度(用能谱分析)、骨转换生化指标(用S环磷酰胺和骨钙素、甲状旁腺素和维生素D)和肌肉功能(核磁共振、肺功能、运动试验)。结果。GLP-2的遵从率为93%。11名患者中有3名没有完成研究。在其余8名患者中，GLP-2显著降低了粪便湿重，从每天约3.0公斤降至约2.0公斤。伴随而来的是口服湿重摄入量的下降，维持肠道湿重吸收和尿重恒定。肾功能改善。能量摄入或吸收没有明显变化，GLP-2对粘膜形态、体成分、骨密度或肌肉功能没有显著影响。结论。GLP-2治疗将粪便重量减少了约1000克/天，并使SBS患者能够在较低的口服摄入量下保持其肠道液体和电解质的吸收。随之而来的是肌酐清除量提高了28%。
Background and aims. In a short-term study, Glucagon-like peptide 2 (GLP-2) has been shown to improve intestinal absorption in short bowel syndrome (SBS) patients. This study describes longitudinal changes in relation to GLP-2 treatment for two years. Methods. GLP-2, 400 micrograms, s.c.,TID, were offered, to eleven SBS patients keeping parenteral support constant. 72-hour nutritional balance studies were performed at baseline, weeks 13, 26, 52 during two years intermitted by an 8-week washout period. In addition, mucosal morphometrics, renal function (by creatinine clearance), body composition and bone mineral density (by DEXA), biochemical markers of bone turnover (by s-CTX and osteocalcin, PTH and vitamin D), and muscle function (NMR, lungfunction, exercise test) were measured. Results. GLP-2 compliance was >93%. Three of eleven patients did not complete the study. In the remaining 8 patients, GLP-2 significantly reduced the fecal wet weight from approximately 3.0 to approximately 2.0 kg/day. This was accompanied by a decline in the oral wet weight intake, maintaining intestinal wet weight absorption and urinary weight constant. Renal function improved. No significant changes were demonstrated in energy intake or absorption, and GLP-2 did not significantly affect mucosal morphology, body composition, bone mineral density or muscle function. Conclusions. GLP-2 treatment reduces fecal weight by approximately 1000 g/d and enables SBS patients to maintain their intestinal fluid and electrolyte absorption at lower oral intakes. This was accompanied by a 28% improvement in creatinine clearance.
登录
查看更多内容
DOI：
10.1249/01.mss.0000166946.94871.9b
发表时间：
2005-06-01
期刊：
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
影响因子：
--
作者：
Nakagawa, Y;Ratkevicius, A;Quistorff, B
通讯作者：
Quistorff, B
DOI：
10.1152/ajpgi.1997.273.6.g1252
发表时间：
1997-12-01
影响因子：
4.5
作者：
Drucker, DJ;DeForest, L;Brubaker, PL
通讯作者：
Brubaker, PL
影响因子：
24.5
作者：
Jeppesen, PB;Staun, M;Mortensen, PB
通讯作者：
Mortensen, PB
影响因子：
--
作者：
Bozkurt, A;Näslund, E;Hellström, PM
通讯作者：
Hellström, PM
影响因子：
24.5
作者：
GLEESON, MH;BLOOM, SR;DOWLING, RH
通讯作者：
DOWLING, RH